The expression of vascular endothelial growth factor is associated with the risk of cancer progression after radical prostatectomy

To analyse the prognostic value of vascular endothelial growth factor (VEGF) in men with clinically localized prostate cancer.

[1]  P. Alken,et al.  The role of the lymphatic system and its specific growth factor, vascular endothelial growth factor C, for lymphogenic metastasis in prostate cancer , 2006, BJU international.

[2]  N. Kinukawa,et al.  Percentage of positive biopsy cores, preoperative prostate‐specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi‐institutional outcome study in Japan , 2006, BJU international.

[3]  M. Peyromaure,et al.  Role of vascular endothelial growth factor in prostate cancer. , 2006, Urology.

[4]  O. Halvorsen,et al.  Is preoperative serum prostate‐specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer? , 2006, BJU international.

[5]  P. Albert,et al.  Long-term salvage radiotherapy outcome after radical prostatectomy and relapse predictors. , 2005, The Journal of urology.

[6]  K. Jennbacken,et al.  Expression of vascular endothelial growth factor C (VEGF‐C) and VEGF receptor‐3 in human prostate cancer is associated with regional lymph node metastasis , 2005, The Prostate.

[7]  A. Partin,et al.  Surgical margin status after radical retropubic prostatectomy , 2005, BJU international.

[8]  M. C. Parkinson,et al.  Radical prostatectomy: pathology findings in 1001 cases compared with other major series and over time , 2005, BJU international.

[9]  T. Wheeler,et al.  Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  P. Scardino,et al.  Expression of vascular endothelial growth factor receptor‐3 (VEGFR‐3) in human prostate , 2004, The Prostate.

[11]  J. Earle,et al.  Long-term follow-up of radical retropubic prostatectomy for prostate cancer. , 2002, European urology.

[12]  C. Kwak,et al.  Thrombospondin‐1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia , 2002, BJU international.

[13]  D. Neal,et al.  Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer , 2001, British Journal of Cancer.

[14]  S. Loening,et al.  Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer , 2000, The Prostate.

[15]  C. Fujiyama,et al.  Elevated serum vascular endothelial growth factor in patients with hormone‐escaped prostate cancer , 2000, BJU international.

[16]  P. Kantoff,et al.  Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. , 1999, Urology.